Format

Send to

Choose Destination
See comment in PubMed Commons below
Thrombosis. 2013;2013:973710. doi: 10.1155/2013/973710. Epub 2013 Apr 10.

New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring.

Author information

  • 1Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, NY 13326, USA.

Abstract

Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants. The recent approval of new oral anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous thromboembolism, especially pulmonary embolism due to their improved pharmacokinetic and pharmacodynamic profiles, predictable anticoagulant response, and lack of required efficacy monitoring. This paper addresses the available literature, on-going clinical trials, highlights critical points, and discusses potential advantages and disadvantages of the new oral anticoagulants in patients with pulmonary embolism.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk